Myeloma is a malignant tumor, but it is a relatively inert malignancy. Myeloma cells, which mainly originate in the bone marrow, cause damage to multiple organs such as blood, bones and kidneys, causing clinical manifestations such as anemia, bone destruction and renal failure and hypercalcemia, and progress relatively slowly. The main causes of human death are recurrent infections, renal failure and complications such as coronary artery disease and ventricular hypertrophy due to anemia. However, the survival of patients with multiple myeloma has been significantly prolonged in recent years due to the continuous development of new drugs and improved efficacy, coupled with the widespread use of autologous stem cell technology.